pyridostigmine bromide has been researched along with transforming growth factor beta in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bolgert, F; Debré, P; Le Garff-Tavernier, M; Leblond, V; Morel, V; Nguyen, S; Vieillard, V | 1 |
1 other study(ies) available for pyridostigmine bromide and transforming growth factor beta
| Article | Year |
|---|---|
Persistence of CD16+/CD56-/2B4+ natural killer cells: a highly dysfunctional NK subset expanded in ocular myasthenia gravis.
Topics: Aged; Anti-Inflammatory Agents; Antigens, CD; Azathioprine; CD56 Antigen; Cholinesterase Inhibitors; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Immunosuppressive Agents; Interferon-gamma; Interleukin-18; Killer Cells, Natural; Lymphocyte Subsets; Male; Membrane Glycoproteins; Myasthenia Gravis; Phenotype; Pyridostigmine Bromide; Receptors, IgG; Receptors, Immunologic; Signaling Lymphocytic Activation Molecule Family; Transforming Growth Factor beta | 2006 |